As FDA puts more emphasis on the potential of postmarket data collection to supplant premarket studies when possible, it raises the likelihood of more Medicare coverage-with-evidence development policies, CMS officials suggest.
Reimbursement considerations for products with less premarket data will also likely take more time to review and require closer collaboration...